NextCure, Inc. (NASDAQ:NXTC – Get Free Report)’s share price crossed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $6.10 and traded as high as $6.41. NextCure shares last traded at $6.34, with a volume of 64,392 shares.
Wall Street Analysts Forecast Growth
Several research analysts have commented on the company. Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday. HC Wainwright restated a “buy” rating on shares of NextCure in a research note on Thursday, August 13th. Finally, Wall Street Zen raised NextCure from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, NextCure presently has an average rating of “Hold” and a consensus target price of $19.00.
Check Out Our Latest Report on NextCure
NextCure Stock Performance
The stock has a fifty day simple moving average of $6.10 and a two-hundred day simple moving average of $7.96. The stock has a market cap of $22.89 million, a PE ratio of -0.73 and a beta of 1.33.
NextCure (NASDAQ:NXTC – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.85).
Insider Buying and Selling at NextCure
In other news, major shareholder Adar1 Capital Management, Llc purchased 36,303 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average cost of $4.94 per share, with a total value of $179,336.82. Following the acquisition, the insider owned 722,419 shares in the company, valued at approximately $3,568,749.86. This trade represents a 5.29% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have acquired 47,154 shares of company stock valued at $233,041 in the last ninety days. 11.90% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On NextCure
A hedge fund recently raised its stake in NextCure stock. Renaissance Technologies LLC increased its holdings in NextCure, Inc. (NASDAQ:NXTC – Free Report) by 80.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 60,534 shares of the company’s stock after acquiring an additional 26,900 shares during the quarter. Renaissance Technologies LLC owned approximately 1.68% of NextCure worth $647,000 as of its most recent filing with the SEC. Institutional investors own 42.65% of the company’s stock.
About NextCure
NextCure, Inc (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells.
NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.
Founded in 2015 and headquartered in the United States, NextCure has operated primarily as a research and development company serving the global oncology market through clinical trials and collaborations.
Featured Articles
- Five stocks we like better than NextCure
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.
